XML 105 R74.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Total revenue $ 244,061 $ 3,550
Research and development (129,643) (173,629)
Net income (loss) 87,014 (187,353)
Reportable Segment    
Segment Reporting Information [Line Items]    
Total revenue 244,061 3,550
Compensation costs (excluding stock based compensation) (45,331) (48,084)
Other segment items (12,101) (13,917)
Net income (loss) 87,014 (187,353)
Reportable Segment | Rinvatercept program expenses    
Segment Reporting Information [Line Items]    
Research and development (7,081) (16,090)
Reportable Segment | Elritercept program expenses    
Segment Reporting Information [Line Items]    
Research and development (38,030) (44,319)
Reportable Segment | Cibotercept program expenses    
Segment Reporting Information [Line Items]    
Research and development (12,562) (29,777)
Reportable Segment | Preclinical & development expenses    
Segment Reporting Information [Line Items]    
Research and development (6,847) (12,008)
Reportable Segment | Other external costs    
Segment Reporting Information [Line Items]    
Research and development $ (35,095) $ (26,708)